You just read:

Ampio Pharmaceuticals Reports Positive Results for both Primary and Secondary Endpoints of Pivotal Phase 3 Trial of Ampion™ in Severe Osteoarthritis-of-the Knee (OAK)

News provided by

Ampio Pharmaceuticals, Inc.

Dec 14, 2017, 06:15 EST